Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 31, 2011. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) rather than a comprehensive financial report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting a specific share transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The only reported activity is the exercise of share options and subsequent sale of shares by a senior executive.
Management Commentary and Risks
There is no management commentary, guidance, outlook, or discussion of risks and contingencies in this specific filing. The document strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(a).
Important Facts for Investors
- Executive Transaction: Mr. D S Redfern exercised options on 45,000 Ordinary shares on October 31, 2011.
- Option Details: The options were granted on December 3, 2002, under the GlaxoSmithKline Share Option Plan with an exercise price of £11.79 per share.
- Share Sale: Immediately following the exercise, 45,000 Ordinary shares were sold on October 31, 2011, at a price of £13.93 per share.
- Notification: The Company and the individual were advised of this transaction on October 31, 2011.